About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. is engaged in the development and
commercialization of autologous cell therapies for the treatment of
various cancers. The company's lead product candidate, Contego™, is a
ready-to-infuse autologous cell therapy utilizing tumor infiltrating
lymphocytes for the treatment of patients with Stage IV metastatic
melanoma. Contego™ is based on a currently available physician-sponsored
investigational therapy at the National Cancer Institute, MD Anderson
Cancer Center and the H. Lee Moffitt Cancer & Research Institute for the
treatment of Stage IV metastatic melanoma. For more information, please
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve significant risks and uncertainties.
Such statements may include, without limitation, statements with respect
to the Company's plans, objectives, projections, expectations and
intentions and other statements identified by words such as "projects,"
"may," "will," "could," "would," "should," "believes," "expects,"
"anticipates," "estimates," "intends," "plans," "potential" or similar
expressions. These statements are based upon the current beliefs and
expectations of the Company's management and are subject to significant
risks and uncertainties, including those detailed in the Company's
filings with the Securities and Exchange Commission and those that
relate to the Company's ability to leverage the expertise of employees
and partners to assist the Company in the execution of its strategy.
These forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially, including market
conditions, risks associated with the cash requirements of the company's
business and other risks detailed from time to time in the company's
filings with the Securities and Exchange Commission, and represent the
company's views only as of the date they are made and should not be
relied upon as representing the company's views as of any subsequent
date. The Company is a development-stage company that will require
significant capital and other resources to develop its currently
unproven technology. The Company does not currently have the capital or
resources required to develop this technology into a revenue producing
asset. Furthermore, the Company will need to expand its current
management team and other personnel to achieve its technological and
financial objectives. The Company undertakes no obligation to publicly
update any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
Anne Marie Fields, 212-838-3777
Senior Vice President
Source: Genesis Biopharma, Inc.